Property | Value |
Name | Spectrophotometric Analysis of the Binary Mixture Containing Cefixime and Ornidazole |
Description | Original article
Ruba N. Shdeed1,*, Mahrous S. Mohamed1, Ekram M. Hassan2
Affiliation:- 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Beirut Arab University, Beirut, Lebanon 2Department of Analytical Chemistry and Quality Control, Faculty of Pharmacy, Beirut Arab University, Beirut, Lebanon
The name of the department(s) and institution(s) to which the work should be attributed: Department of Pharmaceutical Chemistry, Beirut Arab University, Beirut, Lebanon
Address reprint requests to Ruba N. Shdeed. Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Beirut Arab University, Beirut, Lebanon
Article citation: Shdeed RN, Hassan EM, Mahrous MS. Spectrophotometric Analysis of the Binary Mixture Containing Cefixime and Ornidazole. J Pharm Biomed Sci. 2014; 04(09):786-796. Available at www.jpbms.info
ABSTRACT Two spectrophotometric methods are presented for the determination of the binary mixture containing cefixime and ornidazole in a combined dosage form without prior separation. The first method is the zero-crossing derivative method (D) where cefixime was determined by measuring the D1 amplitudes at 309.5 nm, 318.6 nm and 277 nm, in methanolic, aqueous and acidic solutions, respectively; and the D2 amplitudes at 246.5 nm and 297.4 nm, in methanolic and aqueous solutions, respectively. While ornidazole was determined by measuring the D1 amplitudes at 291.5 nm, 286.2 nm and 284.5 nm in methanolic, aqueous and acidic solutions, respectively; and the D2 amplitudes at 312 nm and 306.9 nm, in methanolic and aqueous solutions, respectively. The second method is the derivative ratio method (DD) where cefixime and ornidazole were determined in methanolic solutions by measuring the amplitudes of DD1 at 274 nm and 251 nm, respectively; and DD2 amplitudes in aqueous solutions at 252.5 nm and 278.3 nm, respectively; while the amplitude measurement of DD3 was only successful in cefixime determination in the latter solution at 306.9nm. Also, DD1 amplitude measurements of the acidic solutions at 310 nm and 286.9nm for cefixime and ornidazole, respectively; while DD2 amplitude measurements of the acidic solutions was useful in ornidazole determination at 276 nm. The methods were linear over the concentration range 4.0-20.0 μgml-1 cefixime and 6.0-30.0 μgml-1 ornidazole. The described methods are rapid, accurate, simple and precise and can be used for quality control of such mixture.
KEYWORDS: Cefixime; ornidazole; binary mixture; derivative method; derivative ratio method.
REFERENCES 1.Tripathi, K.D. Essential of Medical Pharmacology. Jaypee Brothers Medical Publishers (P) Ltd, Fifth edition, New Delhi, 2003. 2.Salinas, F., Berzas Nevado, J.J. and Espinosa Mansilla. A. A new spectrophotometric method for the quantitative multicomponent analysis resolution of mixtures of salicylic acid and salicyluric acids. 1990; Talanta, 37,347. 3.Connors, AK. Reaction Mechanisms in Organic Chemistry. Wiley Interscience, New York, 1973;179: 1235. 4.Wahbi, A.M. and Ebel, S.The use of the first-derivative curves of absorption spectra in quantitative analysis”. Anal. Chim. Acta, 1974; 70:57. 5.El Yazbi, F.A. and Barary, M.H. Determination of some cephalosporins using derivative spectrophotometry; Anal. Lett.,1985;18(B5),629. 6.O’ Haver, T.C. and Green, G.L. Numerical error analysis of derivative spectrometry for the quantitative analysis of mixtures”. Anal. Chem., 1976; 48:312. 7.Fairbrother, J.E. Siam, A. Haskins, N. and Fell, A.F. Development in pharmaceutical analysis. Proc. Anal. Div. Chem. Soc.1978;15:253-267. 8.Bedair, M.M El Yazbi, F.A. and Galal, S.A. Second-derivative spectrophotometric determination of some weakly absorbing drugs in their formulations. Alex. J. Pharm. Sci.1991;5(2):143. 9.Budavoni, S. The Merck Index, thirteenth edition, 2001. 10.Zhang, M., Moore, G.A., Gardiner, S.J. and Begg, E.J. Determination of celecoxib in human plasma and breast milk by high-performance liquid chromatographic assay. J. Chromatogr. B. Biomed Appl., 2006; 830, 245-248. 11.Guidance for Industry; Q2B Validation of Analytical Procedures: Methodology; International Conference on Harmonization (ICH), November 1996. http://www.fda.gov/der/guidance/1320fnl.pdf. 12.European Drug Index, Fourth edition, European Society of Clinical Pharmacy, Deutscher Apotheker Verlag Stuttgart, 1997; 826. 13.Medicines Compendium, 2002; 1290.
Competing interest / Conflict of interest The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Shdeed RN, Hassan EM,Mahrous MS This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Filename | Shdeed RN(786-796).pdf |
Filesize | 1.38 MB |
Filetype | pdf (Mime Type: application/pdf) |
Creator | admin |
Created On: | 09/15/2014 01:46 |
Viewers | Everybody |
Maintained by | Editor |
Hits | 2838 Hits |
Last updated on | 09/15/2014 02:01 |
Homepage | |
CRC Checksum | |
MD5 Checksum |